Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ProAssurance Corporation (NYSE: PRA), a specialty property and casualty insurance holding company focused on medical professional liability, products liability for medical technology and life sciences, and workers’ compensation insurance. These regulatory documents offer detailed information on ProAssurance’s financial condition, segment performance, governance, and its pending merger with The Doctors Company.
ProAssurance’s periodic reports, such as its Form 10-K and Form 10-Q filings (referenced in the company’s earnings releases and 8-Ks), include consolidated financial statements, segment disclosures for Specialty Property and Casualty, Workers’ Compensation Insurance, Segregated Portfolio Cell Reinsurance, Lloyd’s Syndicate, and Corporate, as well as discussions of key ratios, Non-GAAP measures, and risk factors. Investors use these filings to analyze underwriting results, reserve development, investment income, and capital metrics like book value per share and Non-GAAP adjusted book value per share.
The company’s Form 8-K filings highlight specific material events. In 2025, ProAssurance filed multiple 8-Ks to furnish quarterly earnings releases under Item 2.02, report the June 24, 2025 stockholder vote approving the merger agreement with The Doctors Company under Item 5.07, and describe progress on regulatory milestones such as early termination of the Hart-Scott-Rodino waiting period under Item 8.01. Another 8-K filed in December 2025 under Item 5.02 outlines compensatory arrangements for named executive officers in connection with the merger and explains how these payments relate to Section 280G of the Internal Revenue Code.
On Stock Titan, ProAssurance filings are updated as they are released on EDGAR. AI-powered summaries help explain the contents of lengthy documents, highlight key changes from prior periods, and surface important items such as segment results, merger-related disclosures, and executive compensation arrangements. Users can review Forms 10-K and 10-Q for comprehensive financial information, 8-Ks for transaction and earnings announcements, and other filings that document ProAssurance’s regulatory history and its planned transition to a wholly owned subsidiary of The Doctors Company.
ProAssurance Corp executive Jeffrey Patton Lisenby, Executive Vice-President and General Counsel, exercised restricted stock units into common shares of ProAssurance on February 25, 2026. He acquired 17,557 shares of common stock through derivative exercises at a reference price of $24.47 per share, with 7,615 shares disposed of to cover tax liabilities. Following these transactions, he directly owned 98,286 shares of common stock. The related restricted stock units were granted under the company’s 2014 and 2024 equity incentive plans and generally vest in equal annual installments over three years, with potential accelerated vesting upon death, disability, Good Reason termination, or Compensation Committee action.
ProAssurance Corporation files its annual report detailing its 2025 business and a pending merger with The Doctors Company. For the year, net premiums written were $0.9 billion, with total assets of $5.4 billion and shareholders’ equity of $1.3 billion as of December 31, 2025.
Gross premiums written were $1.01 billion, with about 77% from Specialty Property & Casualty, 23% from Workers’ Compensation and the remainder from Segregated Portfolio Cell Reinsurance. The report explains strategy around disciplined underwriting, claims management, and investment income, and outlines extensive risk factors spanning insurance, financial, regulatory, operational and technology risks.
The company describes its March 2025 Merger Agreement under which it would become a wholly owned subsidiary of The Doctors Company. Shareholders have approved the deal and most U.S. insurance regulatory approvals have been obtained, with California and Pennsylvania still reviewing. ProAssurance continues to anticipate closing by June 30, 2026, subject to remaining conditions.
ProAssurance Corporation reported stronger fourth-quarter and mixed full-year 2025 results while advancing its planned merger with The Doctors Company. For the quarter ended December 31, 2025, net income was $33.4 million, or $0.64 per diluted share, and Non-GAAP operating income was $42.4 million, or $0.82 per diluted share, both more than double the prior year’s quarter.
For full-year 2025, net income was $50.9 million, or $0.99 per diluted share, slightly below 2024, but Non-GAAP operating income rose to $83.9 million, or $1.62 per diluted share, from $50.2 million, or $0.98 per diluted share. The consolidated Non-GAAP combined ratio improved to 104.2% for the year and 90.3% in the fourth quarter, helped by $53.1 million of favorable prior-year reserve development in Medical Professional Liability. Book value per share increased to $26.24 from $23.49, and Non-GAAP adjusted book value per share rose to $27.82.
The company highlighted continued premium rate increases in its Specialty P&C segment and stable retention of 84%. Management reiterated that the merger with The Doctors Company is progressing, with multiple state regulatory approvals obtained and remaining reviews in California and Pennsylvania still pending, and continues to be anticipated to close by June 30, 2026, subject to final regulatory approvals.
AllianceBernstein L.P. filed an amended Schedule 13G to report its beneficial ownership of 1,910,053 shares of ProAssurance Corp common stock, representing 3.7% of the class as of December 31, 2025. AllianceBernstein has sole voting power over 1,578,283 shares and sole dispositive power over 1,910,053 shares, with no shared voting or dispositive power. The shares are held for investment purposes in client discretionary advisory accounts, and AllianceBernstein states they are not held to change or influence control of ProAssurance.
The Vanguard Group has reported a significant ownership position in ProAssurance Corp. As of December 31, 2025, Vanguard beneficially owned 5,299,454 shares of ProAssurance common stock, representing 10.3% of the outstanding class.
Vanguard reports shared voting power over 387,020 shares, with no sole voting power, and shared dispositive power over all 5,299,454 shares. The shares are held for Vanguard’s clients, who have rights to dividends and sale proceeds, and no single client holds more than 5% of the class. Vanguard states the holdings are in the ordinary course of business and not for the purpose of changing or influencing control.
The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately, while continuing the same investment strategies.
ProAssurance Corporation reported an equity compensation award to a senior executive. Executive Vice-President, Secretary & General Counsel Jeffrey Patton Lisenby received 23,720 Restricted Stock Units (RSUs) on January 7, 2026 at a cash price of $0 per unit.
Each RSU represents a contingent right to one share of ProAssurance common stock under the 2014 Equity Incentive Compensation Plan. The new award will vest pro rata in one‑third increments in 2027, 2028 and 2029, assuming continued employment, with accelerated vesting upon death, disability, certain employment terminations for “Good Reason,” or as approved by the compensation committee. Settlement will be in ProAssurance shares plus cash approximately equal to applicable taxes. The filing also lists existing RSU holdings of 17,668, 15,372 and 3,981 units from prior grants.
ProAssurance Corporation’s President & CEO, Rand Edward Lewis Jr, reported an equity award in the form of restricted stock units. On January 7, 2026, he received 95,714 Restricted Stock Units (RSUs) at a price of $0 per unit, all held directly.
Each RSU gives a contingent right to one share of ProAssurance common stock under the company’s equity incentive plans. The newly reported RSUs tied to the 2014 Equity Incentive Compensation Plan are scheduled to vest in three equal installments in 2027, 2028, and 2029, as long as he remains employed with ProAssurance or its subsidiaries. Vesting can accelerate if his employment ends because of death, disability, Good Reason under his employment agreement, or by action of the Compensation Committee. When RSUs vest, they will be settled partly in shares and partly in cash to cover estimated taxes.
ProAssurance Corporation disclosed that its Chief Financial Officer, Dana S. Hendricks, received an award of 23,720 Restricted Stock Units (RSUs) on 01/07/2026. Each RSU represents a contingent right to receive one share of ProAssurance common stock under the ProAssurance Corporation 2014 Equity Incentive Compensation Plan.
According to the award terms, these RSUs will vest pro rata in one-third increments in each of the years 2027, 2028 and 2029, as long as the CFO remains continuously employed by ProAssurance or a subsidiary through each vesting date. Vesting will accelerate if employment ends due to death, disability or Good Reason, or by action of the Compensation Committee. The RSUs will be settled in shares of common stock and in cash, with the cash portion approximately equal to federal, state and local taxes.
ProAssurance Corporation reported an equity compensation grant to Kevin Merrick Shook, President of a subsidiary. On January 7, 2026, he received 23,720 Restricted Stock Units (RSUs) under the ProAssurance Corporation 2014 Equity Incentive Compensation Plan. These RSUs vest pro rata in one-third increments in 2027, 2028 and 2029, conditioned on his continued employment, with vesting accelerating upon death, disability, Good Reason as defined in his employment agreement, or action by the Compensation Committee. The RSUs will be settled in shares of ProAssurance common stock and cash to cover estimated taxes. Following this award, he directly holds this new RSU grant and additional RSUs from prior awards, including 17,668, 15,372 and 3,981 units.
ProAssurance Corporation granted equity compensation to a senior executive through restricted stock units. On January 7, 2026, Executive VP/Chief HR Officer Noreen Dishart received 18,477 Restricted Stock Units (RSUs) at a price of $0 per unit under the ProAssurance Corporation 2014 Equity Incentive Compensation Plan. Each RSU represents the right to receive one share of ProAssurance common stock plus a cash amount approximately equal to applicable taxes.
The newly granted RSUs are scheduled to vest in three equal installments in 2027, 2028, and 2029, subject to continued employment, with accelerated vesting upon death, disability, certain qualifying employment terminations, or action by the Compensation Committee. The filing also shows previously granted RSUs with post-transaction balances of 13,763, 3,101, and 11,974 units, all held directly.